9th Jul 2020 09:42
(Alliance News) - Dechra Pharmaceuticals PLC on Thursday said trading in the year to the end of June was robust and in line with management expectations.
The veterinary pharmaceuticals company reported 7% annual revenue growth at constant exchange rates.
Dechra said European pharmaceuticals revenue growth was 8%, while North America pharmaceuticals revenue growth was 5%.
In both the European pharmaceuticals and North American pharmaceuticals segments, trading performance was in line with Dechra's outlook, with expected soft final quarter following its record March performance.
"We are pleased to have delivered another year of solid revenue growth despite the uncertainties arising from Covid-19," said Chief Executive Ian Page.
"This growth has been driven from good market penetration of our core portfolio, successful integration of our acquisitions and through the hard work, dedication, innovation and commitment of our employees," added Page.
FTSE 250-listed Dechra shares were trading 0.1% lower in London on Thursday at 2,922.00 pence each.
The company said it will report its annual results on September 7.
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
DPH.L